-
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
-
Rethinking the Role of RadiationChest radiation may not be necessary for people with intermediate-risk breast cancer.
by Thomas Celona
-
De-escalating Treatment for DCISResearch finds certain people with low-risk DCIS may be able to forgo surgery or radiation.
by Thomas Celona
Cancer Talk
Targeted Therapy Improves Pancreatic Cancer Survival
A recently approved drug that targets RAS proteins meaningfully improves outcomes for people with this difficult-to-treat cancer.
by Sandra Gordon
Bring On the WavesA surfer’s love for the ocean guides her through breast cancer treatment and beyond.
by Cameron Walker
Does Exercise Benefit Children With Cancer?New guidelines recommend children and adolescents with cancer get regular physical activity to mitigate side effects from treatment.
by Erin O’Donnell
Can the CYP2D6 Gene Affect Tamoxifen’s Effectiveness?A recent analysis examined whether CYP2D6 metabolism influences tamoxifen response. The answer isn’t entirely clear.
by Ashley P. Taylor
From the AACR
-
AACR OMB Statement and Call to ActionThe AACR is deeply concerned that proposed OMB regulations would disrupt federal research grant giving, severely weakening a program that has supported American medical innovation for decades.
-
AACR Cancer Disparities Progress ReportThe AACR Cancer Disparities Progress Report 2026 highlights recent progress in reducing cancer disparities and emphasizes the continued need for transformative research.
Video
Cancer Research at a Crossroads
